

# CAI Xiaomin

---

**Tel:** 86+15720802922

**Email:** caixiaomin1993@126.com

**Address:** 140#Hanzhong Road, Nanjing Medical University, Nanjing, Jiangsu 210000, China

## **Educational Background**

**Nanjing Medical University-Bachelor Degree**

09/2011-06/2016

**School:** First Clinical Medical College

**Major:** Clinical medicine

**Average Score:** 90.2/100      **GPA:**4.02/5.0      **Rank:** 10/300

**Nanjing Medical University-Doctoral Degree**

09/2016-06/2021

**School:** First Clinical Medical College

**Major:** Oncology

## **Research**

### **Investigator**

*Molecular mechanism of phosphatase SHP2 degradation induced by small molecular compound A33 and its significance in the treatment of colon cancer.*

#### **Main Duty:**

- Assist in writing the tender.
- Explore the efficacy of A33 in the treatment of colon cancer and verify the related mechanisms in vitro and vivo by using RNA- seq and other techniques.
- Explore the structural basis for degradation of SHP2 by A33.

### **Investigator**

*A study about the molecular mechanism of andrographolide reversing 5-FU resistance by altering NLRP3 activation in tumor microenvironment.*

#### **Main Duty:**

- Identify the target of andrographolide in the perspective of autophagy mediated-NLRP3 inhibition.
- Follow up the clinical trail to verify the efficacy and safety of combining andrographolide with 5-FU for patients with advanced colorectal cancer.

### **Investigator**

*Study on the health screening model for scientific and technological workers in Jiangsu province.*

#### **Main Duty:**

- Establish the research plan and write the headline.
- Formulate a health worker's health status screening form.
- Collect and analyze experimental data.

### **Investigator**

*Guidance of clinical PD-1 antibody individualized therapy based on systemic immunophenotyping and its mechanism.*

#### **Main Duty:**

- Do molecular biology experiments.
- Analyze experimental data.
- Write literature review and concluding report.

### **Publications**

- Jing Sun, Cheng Wang, Yi Zhang, Lingyan Xu, Weijia Fang, Yuping Zhu, Yi Zheng, Xiaofeng Chen, Xiju Xie, Xinhua Hu, Weidong Hu, Jingyu Zheng, Ping Li, Jian Yu, Zhu Mei, **Xiaomin Cai**, Biao Wang, Zhibin Hu, Yongqian Shu, Hongbing Shen, Yanhong Gu *Genomic Signatures Reveal DNA Damage Response Deficiency in Brain Metastases of Colorectal Cancer*. Nature Communications 10, Article number: 3190 (2019)
- Xiaofeng Chen, Tianzhu Qiu, Yingwei Zhu, Jing Sun, Ping Li, Biao Wang, Peinan Lic, **Xiaomin Cai**, Xiao Han, Fengjiao Zhao, Yongqian Shu, Lianpeng Chang, Hua Jiang and Yanhong Gu *A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer*. The oncologist.2019-0164
- Xiao Han, Ying Wang, Jing Sun, Tao Tan, **Xiaomin Cai**, Peinan Lin, Yang Tan, Bingfeng Zheng, Biao Wang, Lingyan Xu, Jiawei Wang, Zhengyi Yu, Qiang Xu, Xingxin Wu, Yanhong Gu *Role of CXCR3 signaling in response to anti-PD-1 therapy* EBioMedicine 2019
- B wang, LXu, Y Ge, **X Cai**, Q Li, Z Yu, J Wang, Y wang, C Lu, D Wang, Y Wang, X Chen, Y Gu *PLOD3 is upregulated in gastric cancer and correlated with clinicopathologic characteristics*. Clin.Lab.2019 ;65:25-30
- Z Mei, Y Shao, P Lin, **X Cai**, B Wang, Y Ding, X Ma, X Wu, Y Xia, D Zhu, Y Shu, Z Fu, Y Gu *SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients*. BMC Cancer, 2018. 18(1): p. 479
- Lingyan Xu, Zhiqiang Qin, Feng Wang, Shuhui Si, Lele Li, Peinan Lin, Xiao Han, **Xiaomin Cai**, Haiwei Yang, Yanhong Gu *Methylenetetrahydrofolate reductase C677T polymorphism and colorectal cancer susceptibility: a meta-analysis*. Biosci Rep. 2017 Dec 22; 37(6): BSR20170917
- **Xiaomin Cai**, Lele Li, Xiaofeng Chen, Bing Wei, Yumeng Lin, Xiangyu Xu, Yang Sun, Wenjie Guo, Qiang Xu, Yanhong Gu *Apatinib, a Small-Molecule Kinase Inhibitor, Encouraging Anti-Cancer Activity in Colon Cancer by inhibiting Wnt-β-Catenin pathway*. Frontiers in Oncology (**Revised**)
- **Xiaomin Cai**, Lele Li, Xiaofeng Chen, Bing Wei, Yumeng Lin, Xiangyu Xu, Yang Sun, Wenjie Guo, Qiang Xu, Yanhong Gu *Apatinib promoted anti-PD-1 therapy in colon cancer via enhanced activation of STAT1-dependent antitumor response and elevation of TMB* (**Contributing**)

### **Academic Achievements and Awards**

- Won *second-class Scholarship of Nanjing Medical University* in 2011-2012, 2012-2013 academic year.
- Won *first-class Scholarship of Nanjing Medical University* in 2013-2014 academic year.
- Awarded *Outstanding student leaders of Nanjing Medical University* in 2013-2014 academic year.
- Won *first-class Scholarship of Nanjing Medical University* in 2018 academic year.
- Awarded *Outstanding graduates of Nanjing Medical University* in 2016.
- Awarded *outstanding person* in the College Student Volunteer Summer Practice of Nanjing Medical University in 2014.

### **Volunteer Experience**

- Volunteer of The 2<sup>nd</sup> Asian Youth Games. 08/2013

### **Certificates**

- Nanjing City on-site primary care training certificate. 12/2012
- Physician qualification certificate. 11/2017